Detailed Narrative
Robust Q2 FY25 Performance Driven by Volume Growth
Clean Science delivered a strong Q2 FY25, with sales improving by 26% year-on-year, primarily volume-led across all segments. EBITDA remained stable quarter-on-quarter at INR95 crores, maintaining a healthy EBITDA margin of 42%. The company reported an overall growth of 30% for the quarter, reflecting positive business momentum and an encouraging market environment.
Gross Margin Compression Amidst Raw Material Headwinds
The company experienced a 250 basis points dip in gross profit margins quarter-on-quarter. This was attributed to an increase in raw material prices, particularly influenced by global geopolitical events. Management opted not to fully pass on these price increases to customers, prioritizing volume retention and market share. Additionally, a shift in product mix, with newer products like pharma intermediates and TBHQ gaining traction, contributed to the margin compression.
HALS Segment Expansion and Ambitious Volume Targets
The HALS segment showed significant progress, with monthly sales volume reaching 135 tons. All four commonly used HALS products (701, 770, 622, 944, 119) are now successfully launched, with approvals and sales commencing for newer offerings. Management expressed high confidence in achieving a HALS volume target of 2,000 tons in calendar year 2025, supported by a complete product basket and expanding global distribution. At optimal utilization, HALS is projected to achieve an EBITDA margin of approximately 25% with an average realization of $6 per unit.
Strategic Capex for New Product Commercialization
Clean Science incurred INR155 crores in capex during H1 FY25, primarily directed towards its subsidiary. A pharma intermediate product, with an estimated capex of INR30 crores and a revenue potential of INR80-90 crores, is on track for launch in Q3 FY25, with revenues expected from Q4 FY25. Furthermore, the company has commenced construction for two new projects: a Performance Chemicals segment (INR150 crores capex, commercializing by June-July 2025) and a water treatment product (another INR150 crores capex, commercializing by December 2025) with a revenue potential of INR300-320 crores.
Operational Efficiency and Capacity Utilization
The parent company is currently operating at 70% capacity utilization, providing ample bandwidth for future growth without immediate capacity additions. Management anticipates that increased HALS volumes and overall capacity utilization will lead to improved yield efficiencies and a more favorable fixed cost distribution per kg, thereby enhancing gross margins. The utilization rate for TBHQ has also seen an increase to 70% in Q2 FY25.
Optimistic Long-Term Growth Outlook
Management conveyed an optimistic outlook for long-term growth, projecting the company's revenue to reach 2.5 times its current levels within the next three years. This ambitious target is underpinned by the company's robust R&D capabilities, which have facilitated the execution of its largest-ever capex plan of approximately INR650 crores over a 2-3 year period, focusing on continuous product innovation and market expansion.